The grades of 17 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Gilead Sciences, Inc. (GILD) shows solid improvement this week. The company’s rating rises from a C to a B. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The company also gets A’s in sales growth, earnings growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GILD stock.
Ophthotech Corp.’s (OPHT) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of OPHT stock.
This week, Myriad Genetics, Inc.’s (MYGN) ratings are up from a C last week to a B. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MYGN stock.
Acceleron Pharma Inc (XLRN) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of XLRN stock.
Esperion Therapeutics, Inc. (ESPR) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ESPR stock.
Insys Therapeutics, Inc. (INSY) improves from a B to a A rating this week. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets A’s in sales growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of INSY stock.
This week, Halozyme Therapeutics, Inc. (HALO) pushes up from a B to a A rating. Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of HALO stock.
Lexicon Pharmaceuticals, Inc. (LXRX) boosts its rating from a C to a B this week. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. For more information, get Portfolio Grader’s complete analysis of LXRX stock.
This is a strong week for Dicerna Pharmaceuticals, Inc. (DRNA). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of DRNA stock.
The rating of Akebia Therapeutics, Inc. (AKBA) moves up this week, rising from a C to a B. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AKBA stock.
Merrimack Pharmaceuticals, Inc. (MACK) gets a higher grade this week, advancing from a C last week to a B. Merrimack Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of MACK stock.
The rating of Vital Therapies, Inc. (VTL) moves up this week, rising from a C to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of VTL stock.
This week, ARIAD Pharmaceuticals, Inc. (ARIA) pushes up from a C to a B rating. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Fate Therapeutics, Inc. (FATE) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of FATE stock.
This week, Idera Pharmaceuticals, Inc.’s (IDRA) ratings are up from a C last week to a B. Idera Pharmaceuticals, Inc. is engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune and inflammatory diseases, cancer, asthma and allergies, and for use as vaccine adjuvants. For more information, get Portfolio Grader’s complete analysis of IDRA stock.
Oncothyreon Inc. (ONTY) earns a A this week, jumping up from last week’s grade of B. Oncothyreon Inc. is a biotechnology company that develops therapeutic approaches to cancer management. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of ONTY stock.
CytRx Corporation (CYTR) is seeing ratings go up from a C last week to a B this week. CytRx Corporation is a biopharmaceutical research and development company that specializes in oncology. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CYTR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
